Ibrutinib Promotes Remission in Chronic Lymphocytic Leukemia

This article originally appeared here.
Share this content:
Ibrutinib Promotes Remission in Chronic Lymphocytic Leukemia
Ibrutinib Promotes Remission in Chronic Lymphocytic Leukemia

(HealthDay News) -- A new drug that targets interactions with the tumor microenvironment promotes remission in patients with relapsed chronic lymphocytic leukemia, according to a study published online June 19 in the New England Journal of Medicine.

As part of a phase 1b-2 study, John C. Byrd, M.D., from The Ohio State University in Columbus, and colleagues treated 85 patients with relapsed chronic lymphocytic leukemia with ibrutinib (PCI-32765) orally once a day, where 51 patients received 420 mg and 34 received 840 mg.

The researchers found that both groups had the same overall response rate of 71%. An additional 20% of the 420-mg group and an additional 15% of the 840-mg group had a partial response with lymphocytosis. The responses were independent of clinical and genomic risk factors. The estimated rate of progression-free survival was 75% and the estimated rate of overall survival was 83% at 26 months. Toxicity was largely grade 1 or 2, including diarrhea, fatigue, and upper respiratory tract infection.

"Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, including patients with high-risk genetic lesions," Byrd and colleagues conclude.

The study was partially funded by Pharmacyclics and Janssen Biotech, the manufacturers of ibrutinib.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs